Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

For advanced prostate cancer, new drug slows disease

04.06.2012
UCSF-led international study shows improved quality of life

A new medication proved effective in slowing the spread of metastatic prostate cancer, while helping to maintain the quality of life, in patients with advanced disease. The phase 3 study was unblinded midway, allowing patients receiving the placebo to instead take the drug because of the favorable results.

The study is the first randomized clinical trial to document expanded benefits among a particular group of prostate cancer patients in whom the disease had spread. The medication, abiraterone acetate -- marketed as Zytiga – also delayed the development of pain and deterioration of the patients' overall condition.

The researchers say the medication could provide new treatment options.

"This drug extended lives and gave patients more time when they weren't experiencing significant pain from the disease,'' said the principal investigator of the international trial, Charles J. Ryan, MD, an associate professor of clinical medicine at the UCSF Helen Diller Family Comprehensive Cancer Center.

"This is an interim analysis, the final analysis should be available in 2014," he said. "But it appears that this medication may lay a foundation for the use of this drug at an earlier stage of prostate cancer, and its benefits may be able to be delivered to a much wider population of patients as a result.''

Ryan will present the data on June 2 at the 48th annual meeting of the American Society of Clinical Oncology in Chicago.

Prostate cancer is the second most common form of cancer in men, with some 30,000 people annually dying from the disease. Approximately one-third of patients require no treatment, because their disease does not metastasize, or spread, while another third are treated and cured. But for the remaining patients, the cancer will recur following treatment or spread to the bones, lymph nodes or other parts of the body. Prostate cancer can turn lethal when it spreads and when it resists standard hormonal therapy.

"These results are the culmination of years of research, and will truly transform the way we take care of patients with advanced prostate cancer,'' said Eric J. Small, MD, a UCSF professor and chief of hematology and oncology at the UCSF Helen Diller Family Comprehensive Cancer Center. He and Ryan have collaborated on the research of this class of medication for about 9 years.

"This is a wonderful milestone in our progress in treating prostate cancer, and provides advanced prostate cancer patients everywhere with an important new weapon to fight their cancer,'' he said.

Last year, the U.S. Food and Drug Administration approved abiraterone acetate for men whose disease had spread and who also were resistant to standard hormonal therapy, known as castration-resistant prostate cancer (CRPC) and had received chemotherapy with docetaxel. The approval was based on a clinical trial that showed the effectiveness of the medication in post-chemotherapy patients with more advanced disease.

In the new trial, the patients' cancer had metastasized and had become resistant to initial hormone therapy, but they were not showing considerable symptoms from the disease and had not yet received any chemotherapy.

The study involved 1,088 men at 151 cancer facilities in North America, Europe and Australia. On average, the patients had been diagnosed with prostate cancer five years earlier.

The patients were administered Zytiga in combination with low-dose prednisone. The trial was unblinded in March after it was determined that the drug delayed the need for chemotherapy and for pain medications, improved survival and quality of life. Zytiga also slowed the spread of cancer from an average of 8 months in the placebo group compared to approximately double the time in the treatment group. The medication demonstrated such clear advantages to patients that an independent monitoring committee recommended that patients receiving the placebo be allowed to receive the active drug.

"This trial with a well-tolerated oral agent slowed the progression of the disease while helping to delay suffering and maintaining quality of life in patients with advanced prostate cancer,'' said Ryan who has been researching the drug since 2004 and helped design the phase 3 study. "These are the goals that we are moving toward in cancer treatment. The treatment of advanced prostate cancer is undergoing a rapid transformation, and this drug is a key component of that transformation.''

The medication, by Janssen Research & Development, LLC targets prostate cancer by blocking the production of hormones produced by the cancer that can stimulate its growth. The medication was first created in a British lab in the 1990s. The manufacturer warns that it should be used with caution in patients who have a history of cardiovascular disease, high blood pressure, low blood potassium, and fluid retention.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.

Follow UCSF
UCSF.edu | Facebook.com/ucsf | Twitter.com/ucsf | YouTube.com/ucsf

Elizabeth Fernandez | EurekAlert!
Further information:
http://www.ucsf.edu

More articles from Health and Medicine:

nachricht Scientists track ovarian cancers to site of origin: Fallopian tubes
23.10.2017 | Johns Hopkins Medicine

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

50th Anniversary at JULABO GmbH

23.10.2017 | Press release

Taming 'wild' electrons in graphene

23.10.2017 | Physics and Astronomy

Mountain glaciers shrinking across the West

23.10.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>